Managing immune-related adverse events

Immune-related adverse events (irAEs) are side effects that can develop when being treated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. These side effects develop because the immune system has been activated by an immunotherapy drug, resulting in a highly active immune response. This immune response can damage healthy tissue or cause autoimmune […]

read more

Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA

The European Association of Urology (EAU) Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition (IKCC) have issued a joint statement about the rejection of ipilimumab and nivolumab for kidney cancer by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The EAU are saying that the CHMP’s decision […]

read more

Latest clinical trial results for the treatment of kidney cancer

These short videos explain the latest results from the following clinical trials, and are published on Oncology Tube: CARMENA – nephrectomy plus sunitinib versus sunitinib alone for advanced renal cell carcinoma (RCC) KEYNOTE 427 – first-line pembrolizumab in metastatic RCC CheckMate-214 – first-line ipilimumab plus nivolumab combination versus sunitinib in metastatic RCC RCC treatment after […]

read more

Negative EMA opinion for the ipilimumab/nivolumab combination

Yesterday it was announced that the combination of ipilimumab and nivolumab has not been recommended by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for the first-line treatment of metastatic renal cell carcinoma (RCC). Bristol-Myers Squibb (BMS), the manufacturers of both ipilimumab and nivolumab, will be pursuing […]

read more

Treatment of metastatic kidney cancer in older patients

A recent meta-analysis evaluating the efficacy of first- and second-line treatment in older metastatic renal cell carcinoma (mRCC) patients (65 years or older) and comparing efficacy between older and younger (less than 65 years) patients, reports that the majority of first-line treatments are not as effective in older patients. The data suggest that a combination of […]

read more

Immunotherapy for non-clear cell kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses various clinical trials of immunotherapy for the treatment of rare subtypes of kidney cancer, such as papillary and chromophobe renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual […]

read more

Patient-reported outcomes show improved quality of life with the nivolumab-ipilimumab combination

Patient-reported outcomes data from the Phase 3 CheckMate-214 trial of the nivolumab-ipilimumab combination in intermediate- and poor-risk advanced renal cell carcinoma (RCC) patients versus sunitinib show significant benefits in disease-related symptoms and improvements to cancer-related quality of life and well-being.  Patients treated with the nivolumab-ipilimumab combination reported fewer kidney cancer symptoms compared to standard treatment with sunitinib. […]

read more

FDA approves nivolumab-ipilimumab combination for advanced kidney cancer

The US Food and Drug Administration (FDA) has granted approval to nivolumab (Opdivo) and ipilimumab (Yervoy) in combination for the first-line treatment of intermediate-risk or poor-risk patients with advanced renal cell carcinoma (RCC), which has previously been untreated. The approval is based on the results from the CheckMate 214 clinical trial, which compared the nivolumab-ipilimumab […]

read more

Ipilimumab-nivolumab combination improves overall survival in metastatic kidney cancer

Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from the phase 3 CheckMate-214 clinical trial have been published online in the New England Journal of Medicine.  Patients with intermediate-risk or poor-risk clear cell renal cell carcinoma (RCC) respond better and survive longer with first-line treatment with the ipilimumab-nivolumab combination than with standard sunitinib treatment. Overall survival rates […]

read more

EAU guidelines for the treatment of first-line metastatic kidney cancer to be updated

Further to the results from recent studies, particularly CheckMate-214, the European Association of Urology (EAU) guidelines for standard first-line treatment for patients with metastatic renal cell carcinoma (RCC) are likely to be updated. The results from CheckMate-214 showed the combination of immunotherapy drugs ipilimumab and nivolumab to be superior to standard first-line treatment with sunitinib in […]

read more
Showing 21 to 30 of 54 results
  TOP